Get the Stockscreener App
2.08
0.48%
-0.010
After Hours:
2.10
0.02
+0.96%
Immunitybio Inc stock is traded at $2.08, with a volume of 41.67M.
It is down -0.48% in the last 24 hours and down -2.80% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.09
Open:
$2.09
24h Volume:
41.67M
Relative Volume:
3.86
Market Cap:
$2.05B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.1443
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-11.86%
1M Performance:
-2.80%
6M Performance:
-26.76%
1Y Performance:
-22.10%
1-Day Range:
$2.00
$2.14
1-Week Range:
$2.00
$2.42
52-Week Range:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.08 | 2.06B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Is ImmunityBio Inc. stock vulnerable to regulatory risksQuarterly Profit Review & Free Long-Term Investment Growth Plans - Bölüm Sonu Canavarı
Rate Hike: Can ImmunityBio Inc. (26CA) stock stage a strong rebound this quarterWeekly Profit Analysis & Weekly Consistent Profit Watchlists - moha.gov.vn
Can ImmunityBio Inc. (26CA) stock withstand sector downturnsRate Hike & Weekly Momentum Stock Picks - Улправда
Can ImmunityBio Inc. stock beat market expectations this quarterQuarterly Market Review & Fast Entry High Yield Stock Tips - DonanımHaber
Why hedge funds are buying ImmunityBio Inc. stockJuly 2025 Momentum & Weekly Momentum Stock Picks - DonanımHaber
Stop Loss: Why ImmunityBio Inc. stock could benefit from AI revolutionTrade Volume Report & Fast Gain Stock Tips - Улправда
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain - Seeking Alpha
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? - Insider Monkey
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion - Yahoo Finance
[Form 4] ImmunityBio, Inc. Insider Trading Activity - Stock Titan
ImmunityBio reports encouraging 3-year bladder cancer treatment data - The Pharma Letter
ImmunityBio (NASDAQ: IBRX) director files insider report with no holdings - Stock Titan
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study - Sahm
ImmunityBio Reports 96% Three-Year Bladder Cancer Survival With Anktiva Plus BCG - marketscreener.com
ImmunityBio reports promising 3-year bladder cancer treatment data - Investing.com India
ImmunityBio reports promising 3-year bladder cancer treatment data By Investing.com - Investing.com Nigeria
Anktiva® with BCG demonstrates 96% survival from bladder cancer - marketscreener.com
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Business Wire
Assessing ImmunityBio (IBRX) Valuation After EMA Backs Anktiva for BCG‑Unresponsive Bladder Cancer - simplywall.st
ImmunityBio Appoints Bruce Wendel to Board - The Globe and Mail
ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025 - marketscreener.com
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.8%Here's Why - MarketBeat
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next - ts2.tech
The Bull Case For ImmunityBio (IBRX) Could Change Following EMA’s Conditional Backing Of ANKTIVA Therapy - Sahm
Can ImmunityBio Inoculate Its Future With Regulatory Wins? - RTTNews
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies - MSN
ImmunityBio’s HCW9218 Study Completion: A Potential Game-Changer for Pancreatic Cancer Treatment - TipRanks
Should EMA’s Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Has The Recent ImmunityBio Share Price Rebound Created An Opportunity In 2025? - Sahm
ImmunityBio (IBRX) climbs 7.76% on Europe expansion - MSN
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Insider Monkey
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
Jefferies Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
ImmunityBio Gains Momentum: Bladder Cancer Care Focus - StocksToTrade
Jefferies raises Immunitybio stock price target to $9 on European regulatory progress - Investing.com
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Sahm
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Immunitybio stock rises after positive EMA recommendation for bladder cancer therapy - Investing.com Australia
Is ImmunityBio Inc a good long term investmentSector Rotation Strategies & Achieve Consistent Profits - earlytimes.in
ImmunityBio Says European Medicines Agency Recommends Conditional Marketing Authorization for Anktiva with BCG for Non-Muscle Invasive Bladder Cancer - marketscreener.com
ImmunityBio Receives EMA Recommendation for ANKTIVA in Europe - TradingView — Track All Markets
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
Armistice Capital LLC Acquires New Position in ImmunityBio, Inc. $IBRX - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Does Anktiva-Driven Revenue Momentum Reshape the Bull Case For ImmunityBio (IBRX)? - Sahm
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Finviz
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):